StockData
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. (TVRD) stock

TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.01−0.09 (-8.18%)

Close on Nov 17, 2026Market cap $13.47MP/E –Yield 0.00%

Tvardi Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Tvardi Therapeutics's total assets was $17.52M at Jun 30, 2026. For fiscal 2025 it was $32.07M, down 8.9% from the year before. Over ten years it grew -11.7% a year on average. The highest annual figure on record is $271.16M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$32.07M-8.9%
FY2024Dec 31, 2024$35.20M-72.0%
FY2023Dec 31, 2023$125.84M-30.9%
FY2022Dec 31, 2022$182.24M-26.2%
FY2021Dec 31, 2021$247.06M-8.9%
FY2020Dec 31, 2020$271.16M+16.4%
FY2019Dec 31, 2019$232.96M+22.1%
FY2018Dec 31, 2018$190.82M+96.7%
FY2017Dec 31, 2017$97.00M+52.0%
FY2016Dec 31, 2016$63.83M-42.4%
FY2015Dec 31, 2015$110.90M+98.3%
FY2014Dec 31, 2014$55.93M+209.3%
FY2013Dec 31, 2013$18.08M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$17.52M-60.0%
Q1 FY2026Mar 31, 2026$25.82M-33.7%
Q4 FY2025Dec 31, 2025$32.07M-8.9%
Q3 FY2025Sep 30, 2025$39.02M-24.0%
Q2 FY2025Jun 30, 2025$43.75M-39.7%
Q1 FY2025Mar 31, 2025$38.95M-56.8%
Q4 FY2024Dec 31, 2024$35.20M-72.0%
Q3 FY2024Sep 30, 2024$51.33M-55.5%
Q2 FY2024Jun 30, 2024$72.50M-46.1%
Q1 FY2024Mar 31, 2024$90.10M-41.2%
Q4 FY2023Dec 31, 2023$125.84M-30.9%
Q3 FY2023Sep 30, 2023$115.34M-46.0%
Q2 FY2023Jun 30, 2023$134.39M-40.7%
Q1 FY2023Mar 31, 2023$153.28M-31.5%
Q4 FY2022Dec 31, 2022$182.24M-26.2%
Q3 FY2022Sep 30, 2022$213.51M-5.1%
Q2 FY2022Jun 30, 2022$226.57M+2.3%
Q1 FY2022Mar 31, 2022$223.87M-10.5%
Q4 FY2021Dec 31, 2021$247.06M-8.9%
Q3 FY2021Sep 30, 2021$225.09M+53.0%
Q2 FY2021Jun 30, 2021$221.45M+31.3%
Q1 FY2021Mar 31, 2021$250.23M+27.6%
Q4 FY2020Dec 31, 2020$271.16M+16.4%
Q3 FY2020Sep 30, 2020$147.14M-44.2%
Q2 FY2020Jun 30, 2020$168.61M+12.7%
Q1 FY2020Mar 31, 2020$196.17M+15.0%
Q4 FY2019Dec 31, 2019$232.96M+22.1%
Q3 FY2019Sep 30, 2019$263.80M+24.0%
Q2 FY2019Jun 30, 2019$149.64M+7.0%
Q1 FY2019Mar 31, 2019$170.59M+111.6%
Q4 FY2018Dec 31, 2018$190.82M+96.7%
Q3 FY2018Sep 30, 2018$212.70M+96.9%
Q2 FY2018Jun 30, 2018$139.89M+18.6%
Q1 FY2018Mar 31, 2018$80.64M+86.2%
Q4 FY2017Dec 31, 2017$97.00M+52.0%
Q3 FY2017Sep 30, 2017$108.05M+34.8%
Q2 FY2017Jun 30, 2017$117.97M–
Q1 FY2017Mar 31, 2017$43.30M–
Q4 FY2016Dec 31, 2016$63.83M–
Q3 FY2016Sep 30, 2016$80.15M–

More Tvardi Therapeutics figures

See a number that looks wrong?